Name: Pexidartinib (PLX3397)
Brand: Selleck Chemicals
SKU: S7818
Availability: InStock
Rating: 5 (129 reviews)

Jump to

Quality Control

Batch: Purity: 99.94%

99.94

Products Often Used Together with Pexidartinib (PLX3397)

Tween 80

It is dissolved in Tween 80 with additional solvents to provide a solution for C57BL/6 mice oral administration of the medication in drinking water.

PEG300

It is dissolved in polyethylene glycol 300 (PEG300) with additional solvents to provide a solution for Swiss mice to study the role of microglia in drug abuse.

Dovitinib (TKI-258)

In combination with Dovitinib, it enhances anti-glioma efficacy in the PDGF-B-driven glioma (PDG) model.

Related Targets	EGFR VEGFR PDGFR FGFR c-Met Src MEK FLT3 HER2 c-Kit
Other CSF-1R Inhibitors	Sotuletinib (BLZ945) GW2580 PLX5622 Edicotinib(JNJ-40346527) Ki20227 CSF1R-IN-1 Sulfatinib Vimseltinib AZD7507 Chiauranib

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
4T1 cells	Cell viability assay	0.01-100 ng/mL	24 h	Treatment with Pexidartinib (0.01-100 ng/mL) for 24 hours did not significantly affect murine 4T1 carcinoma cell number in vitro as measured by crystal violet stain.	30936739
Caco-2 cells	Cytotoxicity assay		48 h	IC50 = 5.43 μM	ChEMBL
Caco-2 cells	Cell Viability Assay		48 h	CC50 = 41.53 μM	ChEMBL
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 84 mg/mL (201.04 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	10%DMSO 1 40%PEG300 2 5%Tween80 3 45%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	7.200mg/ml (17.23mM)	Taking the 1 mL working solution as an example, add 100 μL of 72 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	10.000mg/ml (23.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	10.000mg/ml (23.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.650mg/ml (1.56mM)	Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	417.81	Formula	C₂₀H₁₅ClF₃N₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1029044-16-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F

Mechanism of Action

Targets/IC₅₀/Ki	Kit (Cell-free assay) 10 nM CSF-1R (Cell-free assay) 20 nM Flt3 (Cell-free assay) 160 nM
In vitro	In M-NFS-60, Bac1.2F5 and M-07e cells, Pexidartinib (PLX3397) inhibits the CSF1-dependent proliferation with IC50 of 0.44 μM, 0.22 μMand 0.1 μM, respectively.
Kinase Assay	Kinase assay
Kinase Assay	PLX3397 is identified as a potent CSF-1R and c-KIT kinase inhibitor by using a Scaffold- and X-ray structure-based discovery approach. The IC50 data are from SelectScreen™ profiling service.
In vivo	In MMTV-PyMT mice, Pexidartinib (PLX3397) (40 mg/kg, p.o.) significantly inhibits both steady-state and PTX-induced tumor infiltration by CD45+CD11b+Ly6C−Ly6G−F4/80+. This compound/PTX therapy also results in a significant reduction in CD31+ vessel density within mammary tumors, paralleling induction of apoptosis and necrosis. In C57 mice bearing GL261 tumors, this compound (p.o.) inhibits glioblastoma invasion. In cmo mice, this chemical significantly attenuates autoinflammatory disease by decreasing the erosive bone lesions in tails and paws and the levels of circulating MIP-1α. In mice bearing B16F10 melanomas, this compound (45 mg/kg, p.o.) enhances CD8-mediated immunotherapy of melanoma.
References	[1] https://pubmed.ncbi.nlm.nih.gov/22039576/ [2] https://pubmed.ncbi.nlm.nih.gov/22294205/ [3] https://pubmed.ncbi.nlm.nih.gov/22923495/ [4] https://pubmed.ncbi.nlm.nih.gov/25110953/ [5] https://pubmed.ncbi.nlm.nih.gov/35569511/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-c-Jun / c-Jun / p-ERK / ERK / p-MEK / MEK / p-CSF1R / CSF1R p-c-KIT (Y703) / p-FMS (Y546) / p-AKT (S473) / pS6 (S235-236) / p-ERK		28932635

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04703322	Recruiting	Tenosynovial Giant Cell Tumor	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo	March 15 2021	Phase 2
NCT04635111	Recruiting	Hepatotoxicity\|Tenosynovial Giant Cell Tumor	Daiichi Sankyo	January 7 2021	--
NCT04488822	Active not recruiting	Tenosynovial Giant Cell Tumor	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo	September 25 2020	Phase 3
NCT04223635	Completed	Moderate Hepatic Impairment	Daiichi Sankyo	January 7 2020	Early Phase 1
NCT03291288	Completed	Drug Interaction Potential	Daiichi Sankyo	February 26 2018	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am going to use it for mice experiment. but I am not sure how to dissolve this compound, could you tell me the detail?

Answer:
It can dissolve in 5% DMSO+45% PEG 300+5% Tween 80+ddH2O at 10mg/ml.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Pexidartinib (PLX3397) CSF-1R inhibitor

Chemical Structure

Molecular Weight: 417.81